Advances and challenges in the nanoparticles-laden contact lenses for ocular drug delivery.
Challenges
Contact lens
Drug delivery
Nanoparticles
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
25 Oct 2021
25 Oct 2021
Historique:
received:
24
05
2021
revised:
04
09
2021
accepted:
09
09
2021
pubmed:
17
9
2021
medline:
13
10
2021
entrez:
16
9
2021
Statut:
ppublish
Résumé
The delivery of drugs that target ocular tissues is challenging due to the physiological barriers of the eye like tear dilution, nasolacrimal drainage, blinking, tear turnover rate and low residence time Drug-laden contact lenses can be a possible solution to overcome some of these challenges. Nanoparticles are being extensively studied as novel systems for loading drugs into therapeutic contact lenses. The versatile features of the organic and inorganic nanoparticles and their diverse physicochemical properties make it possible to load and sustain drug release from the contact lenses. Nevertheless, several issues remains to be solved before its clinical application and commercialization such as changes in contact lens swelling (water content), transmittance, protein adherence, surface roughness, tensile strength, ion and oxygen permeability and drug leaching during contact lens manufacture. However, clinical studies demonstrated the potential of therapeutic contact lenses to manage the scientific, commercial and regulatory challenges to make its place in the market. This review highlights the different methodologies used to fabricate nanoparticle-laden contact lenses and highlights the major advances and challenges to commercialization.
Identifiants
pubmed: 34530102
pii: S0378-5173(21)00896-6
doi: 10.1016/j.ijpharm.2021.121090
pii:
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
121090Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.